NCT06017557 Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer
| NCT ID | NCT06017557 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
| Condition | Ovarian Cancer Stage III |
| Study Type | INTERVENTIONAL |
| Enrollment | 151 participants |
| Start Date | 2023-01-02 |
| Primary Completion | 2025-12-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 151 participants in total. It began in 2023-01-02 with a primary completion date of 2025-12-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
PREDAtOOR is a pilot study and this study aims at improving the selection of the best treatment strategy for patients with advanced ovarian cancer by using Camera Vision (CV) to predict outcomes of cyto reduction at the time of Diagnostic laparoscopy.
Eligibility Criteria
Inclusion Criteria: * Patients treated at Fondazione Policlinico Gemelli Hospital, Rome Italy, Trillium -Credit Valley Hospital, Mississauga, Ontario and Princess Margaret Cancer Centre, Toronto, Canada * Patients fit for cytoreductive surgery * Patients with a primary diagnosis of suspect Stage III-IV ovarian cancer * Patients selected for interval cytoreductive surgery after NACT Exclusion Criteria: * Patients with pre-operative Stage I-II disease confined to the pelvis * Patients unfit for surgery * Lack of information about patients' surgical outcomes and clinicopathological characteristics * LGSOC, Clear cell and mucinous, non-epithelial histologic subtypes (if available)
Contact & Investigator
Anna Fagotti, Prof
PRINCIPAL INVESTIGATOR
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Frequently Asked Questions
Who can join the NCT06017557 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Ovarian Cancer Stage III. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06017557 currently recruiting?
Yes, NCT06017557 is actively recruiting participants. Contact the research team at liat.hogen@uhn.ca for enrollment information.
Where is the NCT06017557 trial being conducted?
This trial is being conducted at Roma, Italy.
Who is sponsoring the NCT06017557 clinical trial?
NCT06017557 is sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. The principal investigator is Anna Fagotti, Prof at Fondazione Policlinico Universitario Agostino Gemelli IRCCS. The trial plans to enroll 151 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.